A major contributor to this article appears to have a close connection with its subject. (June 2021) |
Company type | Public |
---|---|
NSE: WOCKPHARMA BSE: 532300 | |
Industry | Pharmaceuticals Health care |
Founded | 1960s |
Founder | Habil Khorakiwala |
Headquarters | Wockhardt Towers, Bandra Kurla Complex, Mumbai, Maharashtra, India |
Area served | Worldwide |
Key people | Habil Khorakiwala (Chairman) Murtaza Khorakiwala (Managing director) Huzaifa Khorakiwala (Executive Director) |
Products | Formulations Biopharmaceuticals Vaccines |
Revenue | ₹2,693 crore (US$320 million) (FY23)[1] |
₹−621 crore (US$−74 million) (FY23)[1] | |
Number of employees | 3,000 (2023) |
Subsidiaries | Morton Grove Pharma[2] |
Website | www |
Footnotes / references [3] |
Wockhardt is an Indian pharmaceutical and biotechnology company headquartered in Mumbai, India. It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).[4] The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France.[5][6]
birlaa
was invoked but never defined (see the help page).